Atea Pharmaceuticals (AVIR) POS AM Prospectus update (post-effective amendment)

Exhibit 23.2

Consent of Independent Registered Public Accounting Firm

We consent to the use of our reports dated February 28, 2022, with respect to the consolidated financial statements of Atea Pharmaceuticals, Inc. and subsidiary, and the effectiveness of internal control over financial reporting, incorporated herein by reference.

/s/ KPMG LLP

Boston, Massachusetts

May 10, 2022